ATP 2016

LUNGTECH – KEY NOTES

 Study treatment:

- SBRT of centrally located NSCLC (T1-T3 N0) - 8 X 7.5 Gy, GD 60Gy, ICRU 83

 Primary endpoint:

to evaluate the freedom of local progression rate at 3 years

 Secondary endpoints:

Timmerman et al , JCO 2006

− acute and late toxicity (stopping rules) − pattern of local and distant recurrence − overall survival and causes of death

 Sites:

− 23 Participating sites have been selected from 7 European countries

German Cancer Consortium (DKTK)